What’s the current market cap for BridgeBio Pharma stock?

BridgeBio Pharma (BBIO) has a market cap of $13bn as of June 17, 2026.

What is the P/E ratio for BridgeBio Pharma stock?

The price to earnings (P/E) ratio for BridgeBio Pharma (BBIO) stock is 0 as of June 17, 2026.

Does BridgeBio Pharma stock pay dividends?

No, BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next BridgeBio Pharma dividend payment date?

BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders.

What is the beta indicator for BridgeBio Pharma?

BridgeBio Pharma (BBIO) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy BridgeBio Pharma stock | $BBIO Share Price

13:30

21:10

04:45

12:25

20:00

About BridgeBio Pharma

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Ticker

$BBIO

Sector

Health

Primary listing

NASDAQ

Employees

837

Headquarters

Palo Alto, United States

Website

bridgebio.com

BridgeBio Pharma Metrics

BasicAdvanced

$13bn

-$3.74

1.02

What the Analysts think about BridgeBio Pharma

Analyst ratings (Buy, Hold, Sell) for BridgeBio Pharma stock.

Bulls say / Bears say

Attruby posted a 24% sequential rise and a 392% year-over-year jump in net sales in Q1 2026, demonstrating strong market traction.

BridgeBio has submitted its NDA for BBP-418 and is on track to file NDAs for encaleret for ADH1 in the first half of 2026 and for ingratinib for achondroplasia in Q3 2026, setting up the company for three potential near-term product launches.

Real-world evidence published on medRxiv shows Attruby reduces the need for diuretic intensification by 43% compared to tafamidis, and an independent study at SCAI showed meaningful improvements in clinical outcomes, supporting Attruby’s differentiated product profile.

BridgeBio missed Q1 2026 EPS estimates, reporting a net loss per share of $0.84 versus consensus of $0.70, highlighting continued profitability challenges.

Attruby’s net product revenue of $180.6 million made up over 92% of BridgeBio’s total Q1 2026 revenues of $194.5 million, showing a significant revenue concentration risk.

BridgeBio generated a net cash outflow of $124.7 million from operating activities in Q1 2026, pointing to substantial cash burn despite having a strong balance sheet.

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.

BridgeBio Pharma Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

BridgeBio Pharma Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BBIO

Capital at risk

Market open

Upcoming events

No upcoming events